Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative motor neuron disease.
• Currently, ALS remains incurable, with diverse etiologies and incompletely understood pathogenic mechanisms.
• Genetic factors account for approximately 20% of ALS cases, presenting a target for specific therapies.

Purpose of the Study:

• To review current gene therapy strategies for ALS, focusing on ALS risk genes.
• To summarize recent findings from preclinical animal studies and clinical trials.
• To highlight emerging gene-targeted therapeutic approaches for ALS.

Main Methods:

• Literature review of current ALS gene therapies.
• Analysis of findings from animal models of ALS.
• Examination of data from ongoing and completed clinical trials.

Main Results:

• Several gene therapy strategies are being developed for ALS, targeting specific genetic risk factors.
• Preclinical studies and early clinical trials show potential but require further investigation.
• Emerging approaches show promise for addressing the genetic underpinnings of ALS.

Conclusions:

• Targeted gene therapies represent a significant therapeutic avenue for the 20% of ALS patients with known genetic causes.
• Continued research into ALS-related genes and novel gene-targeting techniques is crucial.
• Advancing gene therapies holds promise for improving outcomes in genetically defined ALS populations.